Wilmington Savings Fund Society FSB Acquires 265,215 Shares of Johnson & Johnson (NYSE:JNJ)

Wilmington Savings Fund Society FSB lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 112.4% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 501,138 shares of the company's stock after acquiring an additional 265,215 shares during the period. Johnson & Johnson makes up approximately 1.5% of Wilmington Savings Fund Society FSB's investment portfolio, making the stock its 10th largest holding. Wilmington Savings Fund Society FSB's holdings in Johnson & Johnson were worth $81,214,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $27,000. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth approximately $31,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after acquiring an additional 91 shares during the period. Finally, Activest Wealth Management purchased a new position in shares of Johnson & Johnson during the third quarter worth $40,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the company's stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price on the stock. Bank of America reissued a "neutral" rating and issued a $166.00 price target on shares of Johnson & Johnson in a report on Tuesday. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.73.

Johnson & Johnson Price Performance

JNJ stock traded down $0.41 during trading on Thursday, hitting $146.23. The stock had a trading volume of 6,174,458 shares, compared to its average volume of 7,118,662. The company's 50-day moving average price is $157.29 and its two-hundred day moving average price is $156.35. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a market capitalization of $352.07 billion, a P/E ratio of 21.28, a PEG ratio of 2.66 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.66 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. Johnson & Johnson's payout ratio is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.